Leerink Initiates Coverage on Absci Stock with Outperform Rating
Absci (ABSI) shares hit a four-year high after Leerink Partners initiated coverage with an 'Outperform' recommendation, citing the AI-driven drug developer's strong catalyst path.
Tickers: $ABSI